July 16, 2024
In last week's Weekly Report, AABB described that the Food and Drug Administration removed the proposed draft guidance, “Recommendations for Determining Eligibility of Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps),” from the “Therapeutic Products” category. In yesterday’s guidance agenda update, FDA has reincluded that guidance.
Members with questions may contact regulatory@aabb.org.
4550 Montgomery Avenue
Suite 700, North Tower
Bethesda, MD 20814
301.907.6977
